Extennsa Proposal

Executive Summary

Newbot Corporation needs a clear and powerful strategy on how to market Extenssa to surgeons and anesthesia professionals as this product has the potential to revolutionize the treatment of high blood loss surgeries.

Over the years, medical practitioners have stressed the vital need for strong plasma volume expanders to eliminate the risk of hypovolemia or high blood loss during open heart surgeries, accidental trauma surgery and other high risk surgical procedures.

The leading plasma volume expander in the market is currently Albumin. Albumin is the choice of over 70% of surgeons and 30% of anesthesia professionals according to market figures.

To date, no other products have reached market with the potential to surpass the performance of Albumin. That is until Newbot delivered Extenssa.

THE TIME IS NOW.

Extenssa needs to be delivered to market rapidly with a strong marketing strategy to capture this important niche within the medical field. Through this marketing strategy, Extenssa WILL be designated as the “New Standard of Care” for treating hypovolemia.

As a result of this focused strategy, Newbot Corporation will be positioned as “the” plasma volume expander supplier of choice in virtually every targeted medical situation.

Here are the some of the additional key medical benefits of Extenssa.

1. Extennsa ELIMINATES the risk of hyperchloremic metabolic acidosis.

2. Extenssa IS lower in chloride content than albumin, hetastarch or any chloride based products.

3. Urine output is promoted by a factor of 2 to 1 over Albumin.

In order to extol these benefits and efficiently deliver Extenssa to market, a superior marketing strategy is necessary to promote this brand. Additionally, this superior marketing strategy will need to arm Newbot’s sales team with the knowledge to help medical professionals realize the exceptional value of Extenssa.

• This aggressive marketing strategy will take advantage of known media channels.

o Immediately, advertisements will be published in major medical journals lauding the superiority of Extenssa over other products in the market, using supporting medical studies.

o Direct mail delivers results. To target our core audience of surgeons, an extensive direct mail campaign will be launched shortly. This campaign will initially focus on those medical professionals that fit the mold of “high-potential” customers.

o A targeted trade show marketing campaign will immediately follow the direct mail campaign. These trade shows will be chosen on the relevancy to the targeted medical professionals. Extenssa will be driven through a strong “meet and greet” promotion campaign for key attendees at each trade